EuroPCR In Brief
This article was originally published in The Gray Sheet
Device trial data at the EuroPCR 2015 conference, held in Paris May 19-22, featured presentations on TAVR, stents and drug-coated balloons.
You may also be interested in...
Principle investigator on the Evolve II trial is optimistic the stent will dominate the U.S. market in two to three years.
The firm announced the CE mark and European launch of its transcatheter aortic heart valve replacement device Oct. 28. Boston is one of at least seven firms with a TAVR device now on the market in Europe.
Recent debuts include NuVasive’s PCM cervical disk system, Boston Scientific’s bioabsorbable Synergy drug-eluting stent in Europe and Medtronic’s MRI-safe Advisa pacemaker in Japan.